DK1105409T3 - Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter - Google Patents

Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter

Info

Publication number
DK1105409T3
DK1105409T3 DK00936023T DK00936023T DK1105409T3 DK 1105409 T3 DK1105409 T3 DK 1105409T3 DK 00936023 T DK00936023 T DK 00936023T DK 00936023 T DK00936023 T DK 00936023T DK 1105409 T3 DK1105409 T3 DK 1105409T3
Authority
DK
Denmark
Prior art keywords
peptide
terminus
peptidase activity
amino acid
protection
Prior art date
Application number
DK00936023T
Other languages
Danish (da)
English (en)
Inventor
Dominique P Bridon
Alan M Ezrin
Peter G Milner
Darren L Holmes
Karen Thibaudeau
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of DK1105409T3 publication Critical patent/DK1105409T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00936023T 1999-05-17 2000-05-17 Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter DK1105409T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
US15978399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
DK1105409T3 true DK1105409T3 (da) 2006-07-03

Family

ID=27384581

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00936023T DK1105409T3 (da) 1999-05-17 2000-05-17 Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter

Country Status (11)

Country Link
EP (5) EP1591453A1 (fr)
JP (6) JP4217004B2 (fr)
AT (1) ATE318835T1 (fr)
AU (1) AU765753B2 (fr)
CA (4) CA2499211A1 (fr)
DE (1) DE60026300T2 (fr)
DK (1) DK1105409T3 (fr)
ES (1) ES2257298T3 (fr)
PT (1) PT1105409E (fr)
SI (1) SI1105409T1 (fr)
WO (1) WO2000069900A2 (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2004011498A2 (fr) * 2002-07-31 2004-02-05 Conjuchem Inc. Derives de peptide natriuretique de longue duree
WO2002040510A2 (fr) * 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Fragments peptidiques modifies apparentes au plasminogene et utilisations de ces derniers en tant qu'inhibiteurs de l'angiogenese
EP1355941A2 (fr) 2001-02-02 2003-10-29 ConjuChem, Inc. Derives du facteur de liberation de l'hormone de croissance de longue duree
CA2436399A1 (fr) 2001-02-16 2002-08-29 Conjuchem Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
AU2002251296A1 (en) * 2001-04-18 2002-10-28 The Open University Polypeptides derived from amyloid precursor peptide (app) and their uses
CA2447292A1 (fr) * 2001-05-17 2002-11-21 Ceremedix, Inc. Composes de peptides contrecarrant lessubstances oxygenees et les radicaux libres
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EP1395833B1 (fr) 2001-05-31 2013-02-27 Adlyfe, Inc. Procede de detection de proteines mal pliees
BR0117155A (pt) * 2001-10-18 2004-10-26 Zlatko Ademovic Efeitos aditivos citoprotetivos de duas regiões bioativas do hormÈnio pró-opiomelanocortina
US6822073B2 (en) * 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
CN1753909A (zh) * 2002-03-19 2006-03-29 株式会社康福来 肽,含有该肽的药物组合物和用于治疗癌症的药物组合物
JP2004008027A (ja) * 2002-06-04 2004-01-15 Japan Science & Technology Corp ｃＡＭＰの産生活性を有する新規ペプチド
WO2004011595A2 (fr) * 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
EP1542718B1 (fr) * 2002-09-24 2015-11-11 Dong Xie Inhibiteurs de fusion contre l'infection au vih derives de peptides
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
WO2004039832A2 (fr) * 2002-10-31 2004-05-13 Albany Medical College Peptides associes a la leptine
CA2504953C (fr) 2002-11-07 2013-08-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nouvelle cible pour la therapie angiogenique et anti-angiogenique
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
EP1582223A4 (fr) * 2003-01-10 2007-01-17 Niigata Tlo Corp Vecteur de therapie genique et methode de quantification de proteine ciblee dans des cellules mammiferes ou cultivees consistant a administrer ce vecteur dans le but d'une therapie genique
AU2003210714A1 (en) * 2003-01-29 2004-08-30 Advanced Research And Technology Institute, Inc. Immunoregulating compounds and an associated method
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US20070082363A1 (en) * 2003-04-25 2007-04-12 Lydie Bougueleret Secreted polypeptide species reduced cardiovascular disorders
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
EP1789440A4 (fr) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc Motifs de la famille de polypeptides pancreatiques et polypeptides les renfermant
WO2005090399A1 (fr) * 2004-03-24 2005-09-29 Gifu International Institute Of Biotechnology Anticorps reconnaissant la prolifération/différenciation de différents types de cellules et procédé d'évaluation de la prolifération/différenciation en utilisant l'anticorps
WO2005103712A2 (fr) * 2004-04-20 2005-11-03 Sphingotec Gmbh Utilisation de precurseurs de tachykinines et/ou de fragments de celles-ci dans un diagnostic medical
EP1759001B1 (fr) 2004-04-21 2011-04-13 Enobia Pharma Inc. Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines vers l'os
DE602005026931D1 (de) * 2004-05-13 2011-04-28 Brahms Gmbh Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
EP1814575A4 (fr) 2004-11-24 2010-07-07 Neopro Labs Llc Methodes et compositions pour traiter des troubles
JP4720175B2 (ja) * 2004-12-15 2011-07-13 富士ゼロックス株式会社 マレイミジル基含有材料およびその製造方法
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
ATE528649T1 (de) 2005-02-15 2011-10-15 Adlyfe Inc Verfahren zum nachweis falsch gefalteter proteine und prionen
WO2006108686A2 (fr) * 2005-04-14 2006-10-19 Aic Agonistes bnp
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20080292627A1 (en) * 2005-05-05 2008-11-27 The Board Of Trustees Of The University Of Illinois Compositions and Methods for Treating Mood and Anxiety Disorders
JP2009513627A (ja) * 2005-10-27 2009-04-02 ペプトロン カンパニー リミテッド 生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法
CA2647835A1 (fr) 2006-03-28 2007-10-04 Neopro Labs, Llc Methodes et compositions pour traiter des conditions
WO2008047241A2 (fr) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Peptides du facteur libérateur de corticotrophine modifiés et leurs utilisations
WO2008052043A2 (fr) * 2006-10-24 2008-05-02 Cogenesys, Inc. Protéines de fusion agonistes du récepteur opioïde
US7820623B2 (en) 2006-10-25 2010-10-26 Amgen Inc. Conjugated toxin peptide therapeutic agents
WO2008121767A2 (fr) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Polypeptides cousus
JP2010527377A (ja) 2007-05-17 2010-08-12 ネオプロ ラブス，エルエルシー ペプチドの結晶形および非結晶形
CA2687141C (fr) 2007-05-22 2014-04-01 Amgen Inc. Compositions et procedes pour produire des proteines de fusion bioactives
WO2009023125A1 (fr) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatine et ses utilisations
WO2009033792A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
EP2190450A2 (fr) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Utilisation de l'hormone de concentration de la mélanine et de la met-enkephaline comme agents thérapeutiques
US20100184680A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
WO2009033741A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent thérapeutique
ES2904673T3 (es) * 2008-02-01 2022-04-05 Ascendis Pharma As Profármaco que comprende un conjugado de fármaco-enlazador.
EP2262539B1 (fr) 2008-04-01 2015-07-15 Novo Nordisk A/S Conjugués insuline-albumine
WO2009142727A2 (fr) * 2008-05-19 2009-11-26 Vasogenix Pharmaceuticals, Inc. Peptides liés au gène de la calcitonine (cgrp) dont la séquence a été modifiée
CN102333872B (zh) 2009-02-25 2014-07-09 默沙东公司 在糖工程化的酵母巴斯德毕赤酵母中对半乳糖同化途径的代谢工程化
CN102574904B (zh) * 2009-07-29 2014-11-26 第一三共株式会社 赋予了经粘膜吸收性的胃动素样肽化合物
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
WO2011050471A1 (fr) * 2009-10-28 2011-05-05 University Of Manitoba Peptides dérivés de protéines de graines de pois jaunes
US8715963B2 (en) 2010-02-24 2014-05-06 Merck Sharp & Dohme Corp. Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastoris
JP6054861B2 (ja) * 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
WO2012021876A2 (fr) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
CA2823066A1 (fr) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions contenant des peptides natriuretiques et leurs methodes d'utilisation
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
JP2013179884A (ja) * 2012-03-01 2013-09-12 Mitsubishi Rayon Co Ltd メラニンカスケードに関与する成分を評価するための核酸マイクロアレイ及びメラニンカスケードに関与する成分の評価方法
WO2013172967A1 (fr) 2012-05-17 2013-11-21 Extend Biosciences, Inc Véhicules destinés à améliorer l'administration des médicaments
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
ES2900592T3 (es) * 2013-07-04 2022-03-17 Univ Barcelona Péptidos transportados activamente y resistentes a proteasas como lanzaderas de la BHE y construcciones de lanzadera - carga
EP3094643B1 (fr) * 2014-01-15 2018-10-17 Fyziologicky ustav Akademie ved Ceske republiky, v.v.i. Peptides lipidés pour abaisser la glycémie
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016049359A1 (fr) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
CA2964463C (fr) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Conjugues de vitamine d therapeutiques
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CA2975971C (fr) * 2015-02-22 2024-06-11 Omnix Medical Ltd. Peptides antimicrobiens
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (fr) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (fr) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
EP3436052A4 (fr) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
IL268971B2 (en) 2017-03-01 2024-01-01 Chengdu Huitai Biomedicine Co Ltd A polypeptide, a segment of a polypeptide, its derivation and their applications
EP3600383A4 (fr) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
US20200140482A1 (en) * 2017-06-02 2020-05-07 Lsi Medience Corporation Method for extracting target protein from biological sample and method for analyzing target protein
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
WO2019106193A1 (fr) 2017-12-01 2019-06-06 University Of Copenhagen Hormone peptidique avec un ou plusieurs o-glycanes
EP3773684A1 (fr) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
WO2019197313A1 (fr) 2018-04-09 2019-10-17 Svar Life Science Ab Dosage de glucagon
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi
US20240041982A1 (en) * 2020-11-25 2024-02-08 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
EP4291224A1 (fr) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Polypeptides de phosphatase alcaline et leurs méthodes d'utilisation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
BE795238A (fr) * 1972-02-09 1973-08-09 Schering Ag Derives d'insuline reticules de maniere intramoleculaire, leur procede de preparation et leur utilisation
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DD252539A1 (de) * 1986-09-17 1987-12-23 Berlin Chemie Veb Verfahren zur oralen anwendung biologisch aktiver peptide mit verzoegerter wirkung
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
WO1992017492A1 (fr) 1991-04-05 1992-10-15 Genentech, Inc. INHIBITEURS DE L'AGREGATION PLAQUETTAIRE PRESENTANT UNE SPECIFICITE ELEVEE POUR GP IIbIII¿a?
EP0652765A4 (fr) 1992-06-12 1997-04-09 Des Tyr Dynorphin Partnership Analogues de dynophine des-tyr.
EP0602290B1 (fr) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
WO1996006626A1 (fr) 1994-08-26 1996-03-07 Lee Nancy M Procede analgesique utilisant des analogues de dynorphine tronques au niveau de la terminaison n
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
JP2001512307A (ja) * 1997-02-05 2001-08-21 １１４９３３６ オンタリオ インコーポレーテッド プロエキセンジンをコードするポリヌクレオチドならびにその作製方法および使用
EP1007561B1 (fr) * 1997-11-07 2002-04-17 Conjuchem, Inc. Nouveaux conjugues opioides et supports endogenes
DE69806066T2 (de) * 1997-11-07 2003-02-06 Conjuchem, Inc. Affinitätsmarkierer für menschliches serum albumin
EP1950223A3 (fr) * 1998-03-09 2009-05-13 Zealand Pharma A/S Conjugués peptides pharmacologiquement actifs dotés d'une tendance réduite à l'hydrolyse enzymatique
WO1999048536A2 (fr) * 1998-03-23 1999-09-30 Conjuchem, Inc. Apport local d'agents therapeutiques a action prolongee

Also Published As

Publication number Publication date
JP2009079048A (ja) 2009-04-16
EP1598365A1 (fr) 2005-11-23
EP1105409B1 (fr) 2006-03-01
EP1591453A1 (fr) 2005-11-02
DE60026300T2 (de) 2006-11-16
AU5139300A (en) 2000-12-05
AU765753B2 (en) 2003-09-25
WO2000069900A2 (fr) 2000-11-23
JP2005239736A (ja) 2005-09-08
DE60026300D1 (de) 2006-04-27
CA2373680A1 (fr) 2000-11-23
JP4221392B2 (ja) 2009-02-12
CA2505617A1 (fr) 2000-11-23
JP4219339B2 (ja) 2009-02-04
JP2010168384A (ja) 2010-08-05
WO2000069900A3 (fr) 2001-02-15
ATE318835T1 (de) 2006-03-15
EP1623994A3 (fr) 2008-07-16
PT1105409E (pt) 2006-07-31
EP1105409A2 (fr) 2001-06-13
CA2499211A1 (fr) 2000-11-23
SI1105409T1 (sl) 2006-06-30
JP4217004B2 (ja) 2009-01-28
CA2373680C (fr) 2008-07-29
EP2100901A1 (fr) 2009-09-16
EP1623994A2 (fr) 2006-02-08
CA2623458A1 (fr) 2000-11-23
JP2003508350A (ja) 2003-03-04
WO2000069900A9 (fr) 2002-07-04
ES2257298T3 (es) 2006-08-01
JP2005263807A (ja) 2005-09-29
JP2008150384A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
DK1105409T3 (da) Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
BG101077A (en) New peptides
HK1053128A1 (en) Long lasting fusion peptide inhibitors of viral infection
EA200000685A1 (ru) Комплекс ifnar2/ifn
MX9702152A (es) Clonacion de una aminopeptidasa de membrana, dependiente de la insulina, a partir de vesiculas de glut-4.
EP1452543A3 (fr) RGD (Arg-Gly-Asp) couplé à des neuropeptides
WO2001085777A3 (fr) Peptides therapeutiques formant des pores
WO1996041640A1 (fr) Analogues de la bradykinine utilises comme inhibiteurs selectifs de la thrombine
WO2000070665A3 (fr) Peptides antiangiogeniques durables
TW200602353A (en) Modified secretin and method of synthesizing thereof
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2002099379A3 (fr) Peptides migrant selectivement dans le sein et procedes permettant d'identifier ces peptides au moyen de l'aminopeptidase p
WO2001005418A3 (fr) Moyen de regeneration des tissus
WO2006006954A3 (fr) Peptides selectivement letaux pour des cellules mammiferes transformees et malignes